Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGRX NASDAQ:GRML NASDAQ:TVGN NASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shsN/AGRMLGreenland Mines Ltd. Common Stock$0.36+0.2%$0.48$0.16▼$3.91$43.72M7.613.44 million shs3.27 million shsTVGNTevogen Bio$7.19-16.4%$6.71$4.14▼$75.50$29.94M0.0927,764 shs146,687 shsZYBTZhengye Biotechnology$0.87+0.8%$0.93$0.68▼$13.08$41.07M-2.47148,390 shs1,753 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGRXAgile Therapeutics0.00%0.00%0.00%0.00%0.00%GRMLGreenland Mines Ltd. Common Stock-7.67%+6.41%-25.73%-15.51%+87.21%TVGNTevogen Bio-10.51%-12.87%+13.91%-40.53%-86.87%ZYBTZhengye Biotechnology-1.05%-1.26%-6.52%-3.12%-89.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGRXAgile Therapeutics$1.51$1.49$0.20▼$2.63$10.35M1.58352,864 shsN/AGRMLGreenland Mines Ltd. Common Stock$0.36+0.2%$0.48$0.16▼$3.91$43.72M7.613.44 million shs3.27 million shsTVGNTevogen Bio$7.19-16.4%$6.71$4.14▼$75.50$29.94M0.0927,764 shs146,687 shsZYBTZhengye Biotechnology$0.87+0.8%$0.93$0.68▼$13.08$41.07M-2.47148,390 shs1,753 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGRXAgile Therapeutics0.00%0.00%0.00%0.00%0.00%GRMLGreenland Mines Ltd. Common Stock-7.67%+6.41%-25.73%-15.51%+87.21%TVGNTevogen Bio-10.51%-12.87%+13.91%-40.53%-86.87%ZYBTZhengye Biotechnology-1.05%-1.26%-6.52%-3.12%-89.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGRXAgile Therapeutics 0.00N/AN/AN/AGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/ATVGNTevogen Bio 1.50Reduce$100.001,290.82% UpsideZYBTZhengye Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AGRX, ZYBT, TVGN, and GRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/1/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/22/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026TVGNTevogen Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/4/2026TVGNTevogen Bio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/3/2026TVGNTevogen Bio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $100.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGRXAgile Therapeutics$19.98M0.52N/AN/A($5.51) per share-0.27GRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.42 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($4.48) per shareN/AZYBTZhengye Biotechnology$16.64M2.47N/AN/A$0.93 per share0.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGRXAgile Therapeutics-$14.47M-$3.65N/AN/AN/A-36.24%N/A-147.37%N/AGRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.25N/AN/AN/AN/A-109.40%-98.80%N/ATVGNTevogen Bio-$26.27M-$4.61N/AN/AN/AN/AN/A-472.77%8/13/2026 (Estimated)ZYBTZhengye Biotechnology-$9.98MN/AN/AN/AN/AN/AN/AN/AN/ALatest AGRX, ZYBT, TVGN, and GRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026GRMLGreenland Mines Ltd. Common StockN/A-$0.15N/A-$0.15N/AN/A5/15/2026Q1 2026TVGNTevogen Bio-$2.64-$1.61+$1.03-$1.61N/AN/A4/28/2026Q4 2025ZYBTZhengye BiotechnologyN/A-$0.0750N/A-$0.0750N/A$3.97 million4/1/2026Q4 2025GRMLGreenland Mines Ltd. Common StockN/A$0.01N/A$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGRXAgile TherapeuticsN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGRXAgile TherapeuticsN/A0.560.38GRMLGreenland Mines Ltd. Common StockN/A19.7319.73TVGNTevogen BioN/A0.290.29ZYBTZhengye Biotechnology0.031.140.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGRXAgile Therapeutics10.92%GRMLGreenland Mines Ltd. Common Stock20.07%TVGNTevogen BioN/AZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipAGRXAgile Therapeutics0.50%GRMLGreenland Mines Ltd. Common Stock9.90%TVGNTevogen Bio70.51%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGRXAgile Therapeutics306.86 million6.82 millionNot OptionableGRMLGreenland Mines Ltd. Common Stock5121.24 million109.24 millionN/ATVGNTevogen Bio34.16 million1.23 millionN/AZYBTZhengye Biotechnology27847.39 millionN/AN/AAGRX, ZYBT, TVGN, and GRML HeadlinesRecent News About These CompaniesZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial ResultsApril 28, 2026 | prnewswire.comZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026April 6, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share StructureApril 6, 2026 | globenewswire.comZhengye Biotechnology Holding Ltd ZYBTMarch 28, 2026 | morningstar.comMZhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGMMarch 25, 2026 | tipranks.comZhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGMFebruary 23, 2026 | tipranks.comZhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to ShareholdersFebruary 11, 2026 | markets.businessinsider.comZhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder LetterFebruary 10, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to ShareholdersFebruary 10, 2026 | globenewswire.comWhy Zhengye Biotechnology Holding Limited’s (ZYBT) Stock Is Up 5.27%January 11, 2026 | aaii.comAIs Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 3.8% Concerning?September 14, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd trading resumesAugust 22, 2025 | msn.comZhengye Biotechnology Holding Ltd trading halted, volatility trading pauseAugust 21, 2025 | msn.comZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...July 17, 2025 | wsj.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comZYBT - Zhengye Biotechnology Holding Ltd Chart - MorningstarJune 27, 2025 | morningstar.comMZhengye Biotechnology Holding LtdJune 21, 2025 | morningstar.comMZYBT Zhengye Biotechnology Holding LimitedMay 30, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGRX, ZYBT, TVGN, and GRML Company DescriptionsAgile Therapeutics NASDAQ:AGRXAgile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.36 +0.00 (+0.17%) As of 04:00 PM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.Tevogen Bio NASDAQ:TVGN$7.19 -1.41 (-16.40%) Closing price 04:00 PM EasternExtended Trading$7.14 -0.06 (-0.76%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Zhengye Biotechnology NASDAQ:ZYBT$0.87 +0.01 (+0.79%) Closing price 04:00 PM EasternExtended Trading$0.85 -0.02 (-2.16%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
